



MDBs Vaccine support

World Bank Group

- \$12 billion (*\$6 billion each IBRD and IDA*)
- *+\$4 billion IFC for production capacity*

Asian Development Bank

- \$9 billion (*specific country allocation*)

Others

- Asian Infrastructure Investment Bank
 - \$? Billion (*planned co-financing with other MDBs such as ADB*)
- Inter-American Development Bank
 - mobilized \$1 billion

country-specific & demand driven
technical & financial support
knowledge sharing & learning
monitoring & evaluation
MDB standards
coordination

procurement
waste management
delivery & distribution
strengthening health systems
communication & administration



APVAX Demand from DMCs

WBG approvals

Region	DMC	Amount (\$ M)
Central Asia	Afghanistan	50 M
	Pakistan	200 M
	Tajikistan	25 M
East Asia	Mongolia	19 M
Pacific	Samoa, Tonga, Tuvalu and Vanuatu	19 M
South Asia	Bangladesh	940 M
	Bhutan	10 M
	India	1,500 M
	Maldives	10 M
	Nepal	165 M
	Sri Lanka	84 M
Southeast Asia	Cambodia	95 M
	Indonesia	450 M
	Philippines	400 M
Total Demand:		3,967 M

- Lebanon (21.01.2021)
- Cabo Verde (11.02.2021)
- Mongolia (11.02.2021)
- Tajikistan (11.02.2021)

Also preparing projects in 20 countries in **Africa**, including DRC, Ethiopia, Niger, Mozambique, Tunisia and Eswatini to name a few.

For most African countries, the financing would be on **grant or highly concessional** terms.



What are we struggling with

Bilateral vs. Multilateral Purchase

- As do we so do they
- Pricing (not in negotiations)

Eligibility Criteria

- Supply Shortage (temporary)
- Coordination
- Vaccine acceptance

(ADB) Staff capacity

- Design
- Monitoring

Longterm Planning vs. Client Driven

- It is not only about vaccine procurement
- Investing to be ready for the next one...
- Debt?

*MDB resources are limited so what about climate change? Economic recovery BBB&G?
How to already create pathway back to (new) but better normal?*



Appendix



Advanced Vaccines: ADB & World Bank Eligibility

VACCINE DEVELOPER	MANUFACTURER	ADB ELIGIBILITY	COVAX	WB ELIGIBILITY
Pfizer/BioNTech	USA	Eligible	Selected	Eligible
Moderna	USA/EU	Eligible	Not selected	Modification on project-by-project basis
AstraZeneca	UK	Eligible	Selected	Modification on project-by-project basis
	SK BIO (Korea)	Eligible	Selected	Modification on project-by-project basis
	SII (India)	Eligible	Selected	Modification on project-by-project basis
	SiamBS (Thailand)	Not eligible	Not selected	Not eligible
Johnson & Johnson	USA	Eligibility pending EUL	Selected	Not yet eligible
Novavax	USA	Eligibility pending EUL	Selected	Not yet eligible
	SII (India)	Eligibility pending EUL	Selected	Not yet eligible
Takara Bio	Japan	Not eligible	Not selected	Not eligible
GeneOne Life Science	South Korea	Not eligible	Not selected	Not eligible
Arcturus	Singapore	Not eligible	Not selected	Not eligible
Bharat Biotech	India	Not eligible (Applied for EUL)	Not selected	Not eligible
Sinopharm	PRC	Not eligible (Applied for EUL)	Not selected	Not eligible
Sinovac	PRC	Not eligible (Applied for EUL)	Not selected	Not eligible
Gamalaya	Russia	Not eligible (Applied for EUL)	Not selected	Not eligible



Asia Pacific Vaccine Access Facility (APVAX)

Requirements: Indonesia Example

Adverse impact of the COVID-19 pandemic

- Rising number of COVID-19 cases & fatalities, rising poverty, economic impact

National vaccination allocation plan

- Prioritization plan in line with WHO SAGE on immunization guidelines
- Procurement plan & medical waste management plan

Needs assessment acceptable to ADB

- Assessment of readiness using VIRAT prepared with WHO and UNICEF support

Effective development partner coordination mechanism

- Development Partner coordination mechanism
- WHO and UNICEF are peer reviewers for project

Governor's Letter

- Outlining COVID-19 vaccination allocation plan
- Affirming commitment to following the APVAX vaccine eligibility criteria



APVAX Vaccine Eligibility Criteria

ADB adopted the following criteria for identifying vaccines eligible for ADB financing:

Criterion 1: Vaccine has been selected for procurement via COVAX on behalf of its participating countries;^[1] **or**

Criterion 2: Vaccine manufacturer has been prequalified by WHO; **or**

Criterion 3: Vaccine has been authorized by a Stringent Regulatory Authority (SRA) for manufacture in the SRA country or the SRA has authorized its manufacturer in a non- SRA country

^[1] Vaccines procured under the COVAX Facility will be required to be pre-qualified by WHO or at a minimum have marketing authorization from an SRA. Exceptionally, provided acceptable to the receiving country, Emergency Use Listing by WHO may be acceptable.

Each criterion is standalone. Only one of the three need to be satisfied in order for vaccines to be eligible for ADB financing.